Results of a phase II study investigating ibrutinib monotherapy for relapsed primary or secondary central nervous system lymphoma.
Home / Resource Library / Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)